Unknown

Dataset Information

0

Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis.

ABSTRACT:

SUBMITTER: Schjesvold FH 

PROVIDER: S-EPMC8018100 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
| S-EPMC7862055 | biostudies-literature
Unknown A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
| S-EPMC6659612 | biostudies-literature
Unknown Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
| S-EPMC5570682 | biostudies-literature
Unknown A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
| S-EPMC5482100 | biostudies-literature
Unknown Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure.
| S-EPMC7027539 | biostudies-literature
Unknown Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
| S-EPMC4643003 | biostudies-literature
Unknown A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial.
| S-EPMC4835896 | biostudies-literature
Unknown Bortezomib plus dexamethasone vs thalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
| S-EPMC5980148 | biostudies-literature
Unknown Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment.
| S-EPMC7685974 | biostudies-literature
Unknown Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma.
| S-EPMC5606008 | biostudies-literature